SCHEMBL3489037

SCHEMBL3489037

Cc1cc(C)cc(CCCNS(=O)(=O)c2c(N)cc(Cl)cc2Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
FABP4 P15090 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NR3C1 P04150 5/20 0.39
NR3C2 P08235 5/20 0.39
PGR P06401 3/20 0.39
GAA P10253 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
CYP3A4 P08684 2/20 0.37
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.34
ALOX12 P18054 1/20 0.34
CNR1 P21554 1/20 0.34
NMT1 P30419 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9220298 0.85 ALDH1A1 (0.44) L3MBTL1MEN1KMT2ANR3C1NR3C2
SCHEMBL9220257 0.85 ALDH1A1 (0.42) L3MBTL1MEN1KMT2ANR3C1NR3C2
SCHEMBL9220640 0.84 NR3C1 (0.42) L3MBTL1MEN1KMT2ANR3C1NR3C2
SCHEMBL9214593 0.84 ALDH1A1 (0.58) L3MBTL1MEN1KMT2ANR3C1NR3C2
SCHEMBL3490280 0.81 NR3C1 (0.42) FABP4MEN1KMT2ANR3C1NR3C2
SCHEMBL9213741 0.80 ALDH1A1 (0.53) L3MBTL1MEN1KMT2ANR3C1NR3C2
SCHEMBL3489059 0.79 CYP3A4 (0.47) FABP4MEN1KMT2ANR3C1NR3C2
SCHEMBL3490267 0.79 CYP3A4 (0.47) FABP4MEN1KMT2ANR3C1NR3C2
SCHEMBL9218655 0.79 ALDH1A1 (0.54) L3MBTL1MEN1KMT2ANR3C1NR3C2
SCHEMBL3490788 0.78 CA1 (0.45) L3MBTL1FABP4NR3C1NR3C2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
EP-2007760-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-12-31 EP disclosed
WO-2007108569-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D L3MBTL1 3136/4885FABP4 4087/4885MEN1 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.